Products - Bladder cancer | Topic | NICE

Showing 7 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable [ID6332]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
21 August 2025
Durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating muscle-invasive bladder cancer [ID6168]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
4 February 2026
Suspected Cancer: recognition and referral (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
13 March 2026
Nogapendekin alfa inbakicept with intravesical BCG for previously treated non-muscle-invasive bladder cancer unresponsive to BCG ID6582
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
30 September 2026
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC